134 related articles for article (PubMed ID: 11315565)
21. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
[TBL] [Abstract][Full Text] [Related]
22. The hydrolysis process of the anticancer complex [ImH][trans-RuCl4(Im)2]: a theoretical study.
Chen J; Chen L; Liao S; Zheng K; Ji L
Dalton Trans; 2007 Aug; (32):3507-15. PubMed ID: 17680040
[TBL] [Abstract][Full Text] [Related]
23. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
[TBL] [Abstract][Full Text] [Related]
24. NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.
Alessio E; Messori L
Molecules; 2019 May; 24(10):. PubMed ID: 31137659
[TBL] [Abstract][Full Text] [Related]
25. Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media.
Malina J; Novakova O; Keppler BK; Alessio E; Brabec V
J Biol Inorg Chem; 2001 Apr; 6(4):435-45. PubMed ID: 11372202
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
[TBL] [Abstract][Full Text] [Related]
27. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
Alessio E; Iengo E; Zorzet S; Bergamo A; Coluccia M; Boccarelli A; Sava G
J Inorg Biochem; 2000 Apr; 79(1-4):173-7. PubMed ID: 10830863
[TBL] [Abstract][Full Text] [Related]
28. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
Sava G; Pacor S; Mestroni G; Alessio E
Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212
[TBL] [Abstract][Full Text] [Related]
29. A theoretical study on the hydrolysis process of two Keppler-type antitumor complexes [TzH][trans-RuCl4(Tz)2] and [2-NH2TzH][trans-RuCl4(2-NH2Tz)2].
Chen JC; Chen LM; Liao SY; Zheng KC; Ji LN
Phys Chem Chem Phys; 2009 May; 11(18):3401-10. PubMed ID: 19421541
[TBL] [Abstract][Full Text] [Related]
30. Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents.
Pashkunova-Martic I; Losantos BC; Kandler N; Keppler B
Curr Drug Deliv; 2018; 15(1):134-142. PubMed ID: 28000552
[TBL] [Abstract][Full Text] [Related]
31. Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study.
Levina A; Aitken JB; Gwee YY; Lim ZJ; Liu M; Singharay AM; Wong PF; Lay PA
Chemistry; 2013 Mar; 19(11):3609-19. PubMed ID: 23361836
[TBL] [Abstract][Full Text] [Related]
32. [Hydrolytic property and solution stability of NAMI derivative containing nicotinamide].
Liang Y; Bi W; Yan H; Liang G
Zhongguo Zhong Yao Za Zhi; 2012 Mar; 37(6):818-23. PubMed ID: 22715730
[TBL] [Abstract][Full Text] [Related]
33. Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes.
Messori L; Marcon G; Orioli P; Fontani M; Zanello P; Bergamo A; Sava G; Mura P
J Inorg Biochem; 2003 May; 95(1):37-46. PubMed ID: 12706540
[TBL] [Abstract][Full Text] [Related]
34. Electronic structural investigations of ruthenium compounds and anticancer prodrugs.
Harris TV; Szilagyi RK; McFarlane Holman KL
J Biol Inorg Chem; 2009 Aug; 14(6):891-8. PubMed ID: 19350289
[TBL] [Abstract][Full Text] [Related]
35. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
[TBL] [Abstract][Full Text] [Related]
36. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
37. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.
Brindell M; Stawoska I; Supel J; Skoczowski A; Stochel G; van Eldik R
J Biol Inorg Chem; 2008 Aug; 13(6):909-18. PubMed ID: 18438690
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
Tan C; Hu S; Liu J; Ji L
Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
[TBL] [Abstract][Full Text] [Related]
40. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
Chen J; Chen L; Liao S; Zheng K; Ji L
J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
